Mario Thomas, Ph.D., Dsa, C.Dir. Email & Phone Number

Cambridge, ON, CA

Cambridge, Ontario, Canada

Guelph, Ontario

Precision Biomonitoring provides the environmental and aquaculture sectors with molecular point-of-need tools that detect environmental DNA (eDNA) for the identification of invasive, keystone and at-risk species, and pathogens in aquatic systems. The molecular point-of-need tools are simple to use, give more definitive species identification, under 2 hours.

Guelph, Canada

The Biodiversity Institute is a world leader in understanding the biodiversity of the planet and utilizes that knowledge to develop innovative technologies that provide solutions to problems facing industry, governments and society at large. The Biodiversity Institute leads biodiversity research and development based on genetic sequencing and barcoding.

Toronto, Canada Area

Proteocyte is commercializing a novel diagnostic technology, Straticyte™, to provide robustprognostic assessment of multiple cancers. With Straticyte™ testing, clinicians choosetreatment strategies to best match individual tumor biology of cancer patients. Adoption ofStraticyte™ will save lives, spare patients adverse effects of radical therapy, and.

In 2011, I conceived, architect-ed and founded the International Commercialization Alliance, bringing together 49 founding organizations from 18 countries. The purpose of the alliance is to help continuously improve how its members commercialize research outcomes by sharing knowledge learned from both successes and failures through continuous global.

Toronto, Canada Area

• Obtained several new sources of funding
• Developed a multitude of partnerships and
• Re-organized the structure to engage the clients, partners and stakeholders
• Developed and implemented a new strategic and operating planning process
• Created a sector strategy and four sector advisory boards

Toronto, Canada

• Built the Centre of Excellence for Commercialization (CCR) from the ground up
• Over a period of four years, CCR has delivered $7 million of funding to 86 companies and services to 992, generating over 1500 new jobs, $28 million of co-investment leverage and $149 million of follow-on investments.

• A $100M venture fund which focuses on early-stage life sciences investments in Canada, Europe, and Israel.
• Devised strategy for as many as twelve, multi-million dollar investment candidates in Bio/Agro, chemistry, medical equipment, genomics, and therapeutic products while reducing corporate risk.
• Brought together some of the world’s largest institutional investors and venture capital funds to co-invest in rounds of over $30 Million in life sciences.

Strasbourg, Grand Est, France

• World leader in the discovery and development of medicines derived from the biology and chemical diversity of insects.
• Built a robust discovery and early product development platform with significant automation of routine operations, increasing the rate of discoveries and improving efficiency by over 100x.
• Executed a strategic plan to successfully transfer technology from a university model to a commercial project, raising €20 Million in venture capital financing and €4.3 million in grants.

Vancouver, British Columbia, Canada

• International biotechnology firm with global projects in the fight against infections.
• Improved corporate value through a series of strategic manoeuveurs including the multi-million dollar acquisitions of a US competitor to obtain broad issued patents enhancing core technology and a UK company for its.
• Established two significant research collaborations raising $13 Million in venture capital advancing anti-infective research while tripling the return on investment in the final corporate exit plan.

• An international biopharmaceutical company dedicated to the research, development, and commercialization of products for the prevention and treatment of human illnesses, with a focus in cancer and infectious diseases.
• Implemented a strategic planning process incorporating business development objectives while integrating long-term strategy with annual operating plans.
• Concluded 20 diverse, lucrative transactions in different countries in the world over a 5-year period
• Launched the Canadian commercial operation for the number one drug, 3TC used against HIV and aids becoming a multi-billion dollar product worldwide and more successful than any other treatment while significantly.

MARKETING MANAGER, SPECIALTY PRODUCTS, & NEW PRODUCTS - MEDICAL DIVISIONPromoted multiple times to senior leadership roles in marketing, business development, and branding.

MARKETING, PRODUCT DEVELOPMENT & COMMERCIALIZATION – HOSPITAL PRODUCTS DIVISIONElevated progressively to management roles in marketing, advertising, and commercialization.

Asc, Corporate Governance

Dsa, Business Administration

Ph.D., B.Sc., Chemistry